Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Aligos Therapeutics, Inc. (ALGS)
USD5.77
-0.34 (-5.49%)
US NASDAQ Healthcare Biotechnology
Address
One Corporate Drive 94080
South San Francisco, CA, US
South San Francisco, CA, US
CEO
Lawrence Blatt
Website
aligos.com
IPO
2020-10-16
CIK 1799448 ISIN US01626L2043
Description
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD5.77
-0.34 (-5.49%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
217.2K
Beta
2.26
Float Shares
4.84M
Free Float %
78.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.34% | +0.33% | -23.67% | -17.62% | -14.71% | -35.30% | +38.30% | -80.39% | -99.11% | -98.38% | -98.38% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
5.77
Low
20.00
+246.6%
Consensus
20.00
+246.6%
Median
20.00
+246.6%
High
20.00
+246.6%
DCF (Unlevered)
0.06
-99.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
20.00
+246.6%
|
| All Time | 3 |
8.67
+50.3%
|
Quality scores
Altman Z-Score
-17.94
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-44.6% Q1'26: -100.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+88.3% ★ Q1'26: -4.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-4,190.0%
-
EBIT margin Biotechnology: +0.0%-4,024.9%
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+57.8% Q1'26: +19.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.06× Q1'26: -0.04× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 3 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 3 Rev. Ana. 4 EPS Ana. |
Dec 2029 2 Rev. Ana. 2 EPS Ana. |
Dec 2030 1 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.36M
est: 4.00M (+9.0%)
|
13.91M
est: 12.55M (+10.8%)
|
15.53M
est: 7.97M (+94.9%)
|
3.95M
est: 3.73M (+5.7%)
|
2.19M
est: 2.45M (-10.8%)
|
1.70M
1.70M – 1.70M
-30.6% YoY
|
2.23M
2.23M – 2.23M
+30.9% YoY
|
74.28M
74.28M – 74.28M
+3,238.3% YoY
|
198.97M
198.97M – 198.97M
+167.9% YoY
|
341.88M
341.88M – 341.88M
+71.8% YoY
|
| EBITDA |
-124.54M
est: -2.40M (-5,091.4%)
|
-93.91M
est: -7.53M (-1,147.1%)
|
-85.06M
est: -7.97M (-967.6%)
|
-86.53M
est: -3.73M (-2,217.8%)
|
-87.06M
est: -2.45M (-3,453.0%)
|
-1.70M
-1.70M – -1.70M
+30.6% YoY
|
-2.23M
-2.23M – -2.23M
-30.9% YoY
|
-74.28M
-74.28M – -74.28M
-3,238.3% YoY
|
-198.97M
-198.97M – -198.97M
-167.9% YoY
|
-341.88M
-341.88M – -341.88M
-71.8% YoY
|
| EBIT |
-128.32M
est: -2.40M (-5,248.8%)
|
-97.58M
est: -7.53M (-1,195.9%)
|
-88.13M
est: -7.97M (-1,006.2%)
|
-89.15M
est: -3.73M (-2,288.1%)
|
-87.99M
est: -2.45M (-3,490.9%)
|
-1.70M
-1.70M – -1.70M
+30.6% YoY
|
-2.23M
-2.23M – -2.23M
-30.9% YoY
|
-74.28M
-74.28M – -74.28M
-3,238.3% YoY
|
-198.97M
-198.97M – -198.97M
-167.9% YoY
|
-341.88M
-341.88M – -341.88M
-71.8% YoY
|
| Net Income |
-128.33M
est: -493.21M (+74.0%)
|
-96.05M
est: -332.81M (+71.1%)
|
-87.68M
est: -154.83M (+43.4%)
|
-131.21M
est: -99.77M (-31.5%)
|
-24.19M
est: -89.59M (+73.0%)
|
-67.02M
-68.65M – -65.39M
+25.2% YoY
|
-47.83M
-66.16M – -29.50M
+28.6% YoY
|
-52.75M
-59.11M – 94.86M
-10.3% YoY
|
28.74M
28.74M – 28.74M
+154.5% YoY
|
52.22M
52.22M – 52.22M
+81.7% YoY
|
| SGA |
28.53M
est: 13.76M (+107.4%)
|
26.41M
est: 43.18M (-38.8%)
|
30.62M
est: 40.92M (-25.2%)
|
22.83M
est: 19.17M (+19.1%)
|
20.72M
est: 12.58M (+64.6%)
|
8.73M
8.73M – 8.73M
-30.6% YoY
|
11.43M
11.43M – 11.43M
+30.9% YoY
|
381.48M
381.48M – 381.48M
+3,238.3% YoY
|
1.02B
1.02B – 1.02B
+167.9% YoY
|
1.76B
1.76B – 1.76B
+71.8% YoY
|
| EPS |
-3.22
est: -78.73 (+95.9%)
|
-2.25
est: -53.13 (+95.8%)
|
-3.52
est: -15.66 (+77.5%)
|
-20.94
est: -10.09 (-107.5%)
|
-2.45
est: -9.06 (+73.0%)
|
-6.78
-6.94 – -6.62
+25.2% YoY
|
-4.84
-6.69 – -2.98
+28.6% YoY
|
-1.61
-5.98 – 9.60
+66.7% YoY
|
2.91
2.91 – 2.91
+280.6% YoY
|
5.28
5.28 – 5.28
+81.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-88.00M
OE per share TTM
-8.48
Owner's Yield
-140.29%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
202.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
3
Total invested
20.1K
Insider transactions (90d)
0
Beneficial owners (>5%)
42
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | David Kroin | 7.30M | 9.99% | — | 7.30M | — | — | HC, IN | Delaware | 2023-11-02 | ↗ |
| 2 | Deep Track Biotechnology Master Fund, Ltd. | 7.30M | 9.99% | — | 7.30M | — | — | CO | Delaware | 2023-11-02 | ↗ |
| 3 | Deep Track Capital, LP | 7.30M | 9.99% | — | 7.30M | — | — | IA, OO | Delaware | 2023-11-02 | ↗ |
| 4 | Armistice Capital, LLC | 7.21M | 9.99% | — | 7.21M | — | — | IA, OO | Delaware | 2024-02-14 | ↗ |
| 5 | Steven Boyd | 7.21M | 9.99% | — | 7.21M | — | — | HC, IN | Delaware | 2024-02-14 | ↗ |
| 6 | Alyeska Fund GP, LLC | 7.18M | 9.99% | — | 7.18M | — | — | OO | Delaware | 2024-02-14 | ↗ |
| 7 | Alyeska Investment Group, L.P. | 7.18M | 9.99% | — | 7.18M | — | — | IA | Delaware | 2024-02-14 | ↗ |
| 8 | Anand Parekh | 7.18M | 9.99% | — | 7.18M | — | — | IN | United States of America | 2024-02-14 | ↗ |
| 9 | Lawrence M. Blatt, Ph.D. | 3.89M | 5.30% | 3.89M | — | 3.89M | — | IN | — | 2023-11-06 | ↗ |
| 10 | Wellington Management Company LLP | 3.36M | 7.89% | — | 3.32M | — | — | IA | Delaware | 2022-02-04 | ↗ |
| 11 | EcoR1 Capital, LLC | 3.21M | 11.00% | — | 3.21M | — | 3.21M | IA, OO | Delaware | 2022-02-14 | ↗ |
| 12 | Oleg Nodelman | 3.21M | 11.00% | — | 3.21M | — | 3.21M | HC, IN | United States | 2022-02-14 | ↗ |
| 13 | EcoR1 Capital Fund Qualified, L.P. | 2.95M | 11.00% | — | 2.95M | — | 2.95M | PN | Delaware | 2022-02-14 | ↗ |
| 14 | 10 | 2.51M | 6.20% | 2.51M | — | 2.51M | — | IN | — | 2022-02-10 | ↗ |
| 15 | EIN #00-0000000 | 2.42M | 5.70% | — | 2.42M | — | 2.42M | IA, HC | Jersey, Channel Islands | 2022-02-14 | ↗ |
| 16 | HHLR Advisors, Ltd. | 2.37M | 5.60% | — | 2.37M | — | — | IA | Cayman Islands | 2022-02-14 | ↗ |
| 17 | Hillhouse Investment Management, Ltd. | 2.37M | 5.60% | — | 2.37M | — | — | IA | Cayman Islands | 2022-02-14 | ↗ |
| 18 | Tang Capital Management, LLC | 2.36M | 5.90% | — | 2.36M | — | 2.36M | OO | DELAWARE | 2022-12-27 | ↗ |
| 19 | Baker Bros. Advisors (GP) LLC | 2.08M | 5.30% | 2.08M | — | 2.08M | — | HC, OO | Delaware | 2022-02-14 | ↗ |
| 20 | Baker Bros. Advisors LP | 2.08M | 5.30% | 2.08M | — | 2.08M | — | IA, PN | Delaware | 2022-02-14 | ↗ |
| 21 | Felix J. Baker | 2.08M | 5.30% | 2.08M | — | 2.08M | — | HC, IN | United States | 2022-02-14 | ↗ |
| 22 | Julian C. Baker | 2.08M | 5.30% | 2.08M | — | 2.08M | — | HC, IN | United States | 2022-02-14 | ↗ |
| 23 | Versant Ventures VI GP, L.P. | 1.94M | 5.10% | — | 1.94M | — | 1.94M | PN | — | 2021-05-03 | ↗ |
| 24 | Leonid Beigelman | 1.87M | 4.70% | 1.87M | — | 1.87M | — | IN | — | 2022-02-10 | ↗ |
| 25 | Wellington Group Holdings LLP | 1.30M | 3.06% | — | 1.26M | — | — | HC | Delaware | 2022-02-10 | ↗ |
| 26 | Wellington Investment Advisors Holdings LLP | 1.30M | 3.06% | — | 1.26M | — | — | HC | Delaware | 2022-02-10 | ↗ |
| 27 | Wellington Management Group LLP | 1.30M | 3.06% | — | 1.26M | — | — | HC | Massachusetts | 2022-02-10 | ↗ |
| 28 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 1.21M | 2.83% | — | 1.21M | — | — | PN | — | 2022-02-04 | ↗ |
| 29 | Versant Vantage I GP, L.P. | 862.4K | 2.30% | — | 862.4K | — | 862.4K | PN | — | 2021-05-03 | ↗ |
| 30 | Versant Vantage I, L.P. | 862.4K | 2.30% | 862.4K | — | 862.4K | — | PN | — | 2021-05-03 | ↗ |
| 31 | Adage Capital Management, L.P. | 218.8K | 7.12% | — | 218.8K | — | — | IA, PN | Delaware | 2024-11-12 | ↗ |
| 32 | Phillip Gross | 218.8K | 7.12% | — | 218.8K | — | — | HC, IN | Delaware | 2024-11-12 | ↗ |
| 33 | Robert Atchinson | 218.8K | 7.12% | — | 218.8K | — | — | HC, IN | Delaware | 2024-11-12 | ↗ |
| 34 | Israel A. Englander | 125.5K | 4.10% | — | 125.5K | — | 125.5K | IN | Cayman Islands | 2024-09-12 | ↗ |
| 35 | Millennium Group Management LLC | 125.5K | 4.10% | — | 125.5K | — | 125.5K | OO | Cayman Islands | 2024-09-12 | ↗ |
| 36 | Millennium Management LLC | 125.5K | 4.10% | — | 125.5K | — | 125.5K | OO | Cayman Islands | 2024-09-12 | ↗ |
| 37 | ICS Opportunities II LLC | 123.9K | 4.00% | — | 123.9K | — | 123.9K | OO | Cayman Islands | 2024-09-12 | ↗ |
| 38 | Arsani William | — | 11.00% | — | — | — | — | HC, IN | United States | 2022-02-14 | ↗ |
| 39 | Logos GP LLC | — | 11.00% | — | — | — | — | OO | Delaware | 2022-02-14 | ↗ |
| 40 | Logos Global Management GP LLC | — | 11.00% | — | — | — | — | HC, OO | Delaware | 2022-02-14 | ↗ |
| 41 | Logos Global Management LP | — | 11.00% | — | — | — | — | IA, PN | Delaware | 2022-02-14 | ↗ |
| 42 | Logos Global Master Fund LP | — | 11.00% | — | — | — | — | PN | Cayman Islands | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
3
-36 vs prev Q
New positions
0
Closed positions
36
Increased
0
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | DEEP TRACK CAPITAL, LP | 444.1K +— (+0.0%) | 4.14M -213.2K (-4.9%) | 4.28% -0.008 pp | 0.07% -0.048 pp | USD8.48 +9.9% | 6 qtrs — |
| 2 | ALYESKA INVESTMENT GROUP, L.P. | 412.0K +— (+0.0%) | 3.84M -197.8K (-4.9%) | 3.97% -0.007 pp | 0.01% -0.001 pp | USD8.25 +13.0% | 4 qtrs — |
| 3 | SIO CAPITAL MANAGEMENT, LLC | 335.9K +— (+0.0%) | 3.13M -161.3K (-4.9%) | 3.24% -0.006 pp | 0.49% -0.341 pp | USD7.77 +19.9% | 4 qtrs — |
| 4 | WOODLINE PARTNERS LP | 289.2K -179.0K (-38.2%) | 2.70M -1.9M (-41.3%) | 2.79% -1.735 pp | 0.01% -0.011 pp | USD7.84 +18.9% | 6 qtrs — |
| 5 | MARSHALL WACE, LLP | 268.7K +268.7K (+100.0%) | 2.50M +2.5M (+100.0%) | 2.59% +2.591 pp | 0.00% +0.002 pp | USD9.32 +0.0% | 1 qtrs NEW |
| 6 | VANGUARD GROUP INC | 200.4K +28.7K (+16.7%) | 1.87M +185.1K (+11.0%) | 1.93% +0.274 pp | 0.00% +0.000 pp | USD13.94 -33.1% | 6 qtrs — |
| 7 | SUMMITTX CAPITAL, L.P. | 139.4K +139.4K (+100.0%) | 1.30M +1.3M (+100.0%) | 1.34% +1.345 pp | 0.04% +0.039 pp | USD9.32 +0.0% | 1 qtrs NEW |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 85.4K +30.4K (+55.3%) | 796.3K +257.2K (+47.7%) | 0.82% +0.293 pp | 0.00% +0.001 pp | USD8.57 +8.8% | 6 qtrs — |
| 9 | BAKER BROS. ADVISORS LP | 83.1K +— (+0.0%) | 774.1K -39.9K (-4.9%) | 0.80% -0.001 pp | 0.00% -0.001 pp | USD8.66 +7.6% | 6 qtrs — |
| 10 | TWO SIGMA INVESTMENTS, LP | 80.6K +41.7K (+106.8%) | 751.6K +369.5K (+96.7%) | 0.78% +0.401 pp | 0.00% +0.001 pp | USD9.31 +0.1% | 4 qtrs — |
| 11 | HHLR ADVISORS, LTD. | 76.2K +— (+0.0%) | 710.6K -36.6K (-4.9%) | 0.74% -0.001 pp | 0.02% +0.005 pp | USD8.66 +7.6% | 6 qtrs — |
| 12 | VERITION FUND MANAGEMENT LLC | 71.3K +71.3K (+100.0%) | 664.1K +664.1K (+100.0%) | 0.69% +0.687 pp | 0.00% +0.003 pp | USD9.32 +0.0% | 1 qtrs NEW |
| 13 | LPL FINANCIAL LLC | 66.0K +10.9K (+19.7%) | 615.1K +74.9K (+13.9%) | 0.64% +0.104 pp | 0.00% +0.000 pp | USD8.54 +9.1% | 3 qtrs — |
| 14 | CITADEL ADVISORS LLC | 51.8K +41.5K (+402.8%) | 483.1K +382.1K (+378.1%) | 0.50% +0.400 pp | 0.00% +0.000 pp | USD8.90 +4.7% | 3 qtrs — |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 47.7K +661.0 (+1.4%) | 445.1K -16.5K (-3.6%) | 0.46% +0.006 pp | 0.00% +0.000 pp | USD10.88 -14.3% | 6 qtrs — |
| 16 | JANE STREET GROUP, LLC | 24.3K +24.3K (+100.0%) | 226.4K +226.4K (+100.0%) | 0.23% +0.234 pp | 0.00% +0.000 pp | USD9.32 +0.0% | 1 qtrs NEW |
| 17 | XTX TOPCO LTD | 23.1K +23.1K (+100.0%) | 214.9K +214.9K (+100.0%) | 0.22% +0.222 pp | 0.01% +0.006 pp | USD9.32 +0.0% | 3 qtrs — |
| 18 | QUEST PARTNERS LLC | 13.9K +7.1K (+104.9%) | 129.3K +63.0K (+94.9%) | 0.13% +0.068 pp | 0.01% +0.003 pp | USD8.89 +4.8% | 4 qtrs — |
| 19 | BANK OF AMERICA CORP /DE/ | 13.1K +11.2K (+584.8%) | 122.2K +103.4K (+551.3%) | 0.13% +0.108 pp | 0.00% +0.000 pp | USD9.16 +1.7% | 6 qtrs — |
| 20 | BLACKROCK, INC. | 13.0K +— (+0.0%) | 121.5K -6.3K (-4.9%) | 0.13% 0.000 pp | 0.00% +0.000 pp | USD19.24 -51.6% | 6 qtrs — |
| 21 | TWO SIGMA ADVISERS, LP | 13.0K +13.0K (+100.0%) | 121.2K +121.2K (+100.0%) | 0.13% +0.125 pp | 0.00% +0.000 pp | USD9.32 +0.0% | 1 qtrs NEW |
| 22 | DRW SECURITIES, LLC | 12.0K +12.0K (+100.0%) | 111.4K +111.4K (+100.0%) | 0.12% +0.115 pp | 0.00% +0.003 pp | USD9.32 +0.0% | 1 qtrs NEW |
| 23 | HRT FINANCIAL LP | 11.4K +11.4K (+100.0%) | 106.0K +106.0K (+100.0%) | 0.11% +0.110 pp | 0.00% +0.000 pp | USD9.32 +0.0% | 1 qtrs NEW |
| 24 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 10.0K +9.0K (+900.0%) | 93.2K +83.4K (+851.0%) | 0.10% +0.087 pp | 0.00% +0.000 pp | USD9.37 -0.5% | 2 qtrs — |
| 25 | NORTHCREST ASSET MANANGEMENT, LLC | 10.0K +— (+0.0%) | 84.1K -14.3K (-14.5%) | 0.10% 0.000 pp | 0.00% -0.001 pp | USD9.80 -4.9% | 2 qtrs — |
| 26 | FMR LLC | 5.0K +5.0K (+100.0%) | 46.3K +46.3K (+100.0%) | 0.05% +0.048 pp | 0.00% +0.000 pp | USD9.32 +0.0% | 3 qtrs — |
| 27 | GOLDEN STATE WEALTH MANAGEMENT, LLC | 2.7K +— (+0.0%) | 24.9K -1.3K (-4.9%) | 0.03% +0.000 pp | 0.00% 0.000 pp | USD39.84 -76.6% | 5 qtrs — |
| 28 | MORGAN STANLEY | 2.5K -8.8K (-77.7%) | 23.5K -87.1K (-78.8%) | 0.02% -0.085 pp | 0.00% +0.000 pp | USD13.89 -32.9% | 6 qtrs — |
| 29 | ROYAL BANK OF CANADA | 2.1K +— (+0.0%) | 20.0K -1.0K (-4.8%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD39.84 -76.6% | 5 qtrs — |
| 30 | WELLS FARGO & COMPANY/MN | 1.5K -1.7K (-52.7%) | 14.0K -17.1K (-55.0%) | 0.01% -0.016 pp | 0.00% +0.000 pp | USD38.15 -75.6% | 5 qtrs — |
| 31 | CLEAR STREET MARKETS LLC | 500.00 +500.0 (+100.0%) | 4.7K +4.7K (+100.0%) | 0.00% +0.005 pp | 0.00% +0.001 pp | USD9.32 +0.0% | 1 qtrs NEW |
| 32 | GLOBAL RETIREMENT PARTNERS, LLC | 400.00 -400.0 (-50.0%) | 3.7K -4.1K (-52.4%) | 0.00% -0.004 pp | 0.00% 0.000 pp | USD9.80 -4.9% | 2 qtrs — |
| 33 | UBS GROUP AG | 364.00 -15.8K (-97.8%) | 3.4K -155.2K (-97.9%) | 0.00% -0.153 pp | 0.00% +0.000 pp | USD14.88 -37.4% | 6 qtrs — |
| 34 | JPMORGAN CHASE & CO | 306.00 -402.0 (-56.8%) | 2.9K -4.1K (-58.9%) | 0.00% -0.004 pp | 0.00% +0.000 pp | USD9.75 -4.4% | 6 qtrs — |
| 35 | TOWER RESEARCH CAPITAL LLC (TRC) | 39.00 -418.0 (-91.5%) | 363.00 -4.1K (-91.9%) | 0.00% -0.004 pp | 0.00% 0.000 pp | USD24.33 -61.7% | 6 qtrs — |
| 36 | SBI SECURITIES CO., LTD. | 26.00 +— (+0.0%) | 242.00 -13.0 (-5.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD27.27 -65.8% | 5 qtrs — |
| 37 | ZRC WEALTH MANAGEMENT, LLC | 4.00 +— (+0.0%) | 38.00 -2.0 (-5.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.50 +9.6% | 6 qtrs — |
| 38 | BNP PARIBAS ARBITRAGE, SNC | 3.00 +— (+0.0%) | 28.00 -1.0 (-3.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD7.00 +33.1% | 6 qtrs — |
| 39 | CITIGROUP INC | 1.00 +1.0 (+100.0%) | 9.00 +9.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD9.00 +3.6% | 1 qtrs NEW |
| 40 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | — -10.1K (-100.0%) | — -99.0K (-100.0%) | 0.00% -0.098 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 41 | READYSTATE ASSET MANAGEMENT LP | — -203.1K (-100.0%) | — -2.0M (-100.0%) | 0.00% -1.962 pp | 0.00% -0.085 pp | USD— | 4 qtrs SOLD |
| 42 | ADAGE CAPITAL PARTNERS GP, L.L.C. | — -140.0K (-100.0%) | — -1.4M (-100.0%) | 0.00% -1.353 pp | 0.00% -0.002 pp | USD— | 6 qtrs SOLD |
| 43 | BARCLAYS PLC | — -15.0 (-100.0%) | — -147.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 44 | SQUAREPOINT OPS LLC | — -30.5K (-100.0%) | — -298.8K (-100.0%) | 0.00% -0.295 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 17 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 108.8K | 0.60% |
| 2 | U.S. Micro Cap Portfolio ETF DFMC | 0.00% | 57.6K | 0.43% |
| 3 | Dimensional - US Sustainability Core 1 ETF DFSU | 0.00% | 7.8K | 0.15% |
| 4 | Avantis U.S. Small Cap Equity ETF AVSC | 0.00% | 9.4K | 0.25% |
| 5 | Vanguard Extended Market ETF VXF | 0.00% | 260.6K | 0.05% |
| 6 | Dimensional - US Small Cap ETF DFAS | 0.00% | 19.0K | 0.26% |
| 7 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 1.5K | 0.03% |
| 8 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 311.02 | 0.17% |
| 9 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 4.2K | 0.17% |
| 10 | Vanguard Total Stock Market ETF VTI | 0.00% | 719.7K | 0.03% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
3
Sells
0
Shares acquired
152.8K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+152,775
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-09 | Calhoun Lesley Ann | Officer | A-Award | A | Stock Option (Right to Buy) | 37,485 | 7.03 | 263.5K | 37,485 | D | ↗ |
| 2026-03-09 | BLATT LAWRENCE | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 105,840 | 7.03 | 744.1K | 105,840 | D | ↗ |
| 2026-03-09 | Aneja Nikhil | Officer | A-Award | A | Stock Option (Right to Buy) | 9,450 | 7.03 | 66.4K | 9,450 | D | ↗ |
| 2026-01-29 | Aneja Nikhil | Officer | — | — | Stock Option (Right to Buy) | 3,800 | 16.00 | 60.8K | 0 | D | ↗ |
| 2025-07-16 | Symons Julian A. | Officer | A-Award | A | Stock Option (Right to Buy) | 16,000 | 8.68 | 138.9K | 16,000 | D | ↗ |
| 2025-07-16 | Calhoun Lesley Ann | Officer | A-Award | A | Stock Option (Right to Buy) | 40,185 | 8.68 | 348.8K | 40,185 | D | ↗ |
| 2025-07-16 | BLATT LAWRENCE | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 179,800 | 8.68 | 1.56M | 179,800 | D | ↗ |
| 2025-06-25 | Scopa James Paul | Director | A-Award | A | Stock Option (Right to Buy) | 5,860 | 7.63 | 44.7K | 5,860 | D | ↗ |
| 2025-06-25 | Preston Heather | Director | A-Award | A | Stock Option (Right to Buy) | 5,860 | 7.63 | 44.7K | 5,860 | D | ↗ |
| 2025-06-25 | Nuechterlein Carole | Director | A-Award | A | Stock Option (Right to Buy) | 5,860 | 7.63 | 44.7K | 5,860 | D | ↗ |
| 2025-06-25 | Martell Bridget A | Director | A-Award | A | Stock Option (Right to Buy) | 5,860 | 7.63 | 44.7K | 5,860 | D | ↗ |
| 2025-06-25 | Hirth Peter | Director | A-Award | A | Stock Option (Right to Buy) | 5,860 | 7.63 | 44.7K | 5,860 | D | ↗ |
| 2025-06-25 | Chavez Margarita | Director | A-Award | A | Stock Option (Right to Buy) | 5,860 | 7.63 | 44.7K | 5,860 | D | ↗ |
| 2025-02-28 | Symons Julian A. | Officer | A-Award | A | Stock Option (Right to Buy) | 21,693 | 16.87 | 366.0K | 21,693 | D | ↗ |
| 2025-02-28 | Calhoun Lesley Ann | Officer | A-Award | A | Stock Option (Right to Buy) | 47,271 | 16.87 | 797.5K | 47,271 | D | ↗ |
| 2025-02-28 | BLATT LAWRENCE | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 140,103 | 16.87 | 2.36M | 140,103 | D | ↗ |
| 2024-10-08 | Achneck Hardean | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 7.32 | 549.0K | 75,000 | D | ↗ |
| 2024-09-23 | Achneck Hardean | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-09-04 | Symons Julian A. | Officer | A-Award | A | Stock Option (Right to Buy) | 10,880 | 11.74 | 127.7K | 10,880 | — | ↗ |
| 2024-09-04 | Calhoun Lesley Ann | Other | A-Award | A | Stock Option (Right to Buy) | 10,880 | 11.74 | 127.7K | 10,880 | — | ↗ |
| 2024-09-04 | BLATT LAWRENCE | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 33,920 | 11.74 | 398.2K | 33,920 | — | ↗ |
| 2024-08-07 | Preston Heather | Director | A-Award | A | Stock Option (Right to Buy) | 120,000 | 0.55 | 66.0K | 120,000 | — | ↗ |
| 2024-08-07 | Chavez Margarita | Director | A-Award | A | Stock Option (Right to Buy) | 120,000 | 0.55 | 66.0K | 120,000 | — | ↗ |
| 2024-06-27 | Scopa James Paul | Director | A-Award | A | Stock Option (Right to Buy) | 60,000 | 0.38 | 22.8K | 60,000 | — | ↗ |
| 2024-06-27 | Nuechterlein Carole | Director | A-Award | A | Stock Option (Right to Buy) | 60,000 | 0.38 | 22.8K | 60,000 | — | ↗ |
| 2024-06-27 | Martell Bridget A | Director | A-Award | A | Stock Option (Right to Buy) | 60,000 | 0.38 | 22.8K | 60,000 | — | ↗ |
| 2024-06-27 | Hirth Peter | Director | A-Award | A | Stock Option (Right to Buy) | 60,000 | 0.38 | 22.8K | 60,000 | — | ↗ |
| 2024-03-01 | Symons Julian A. | Officer | A-Award | A | Stock Option (Right to Buy) | 72,000 | 1.13 | 81.4K | 72,000 | — | ↗ |
| 2024-03-01 | McClure Matthew W. | Officer | A-Award | A | Stock Option (Right to Buy) | 72,000 | 1.13 | 81.4K | 72,000 | — | ↗ |
| 2024-03-01 | Calhoun Lesley Ann | Other | A-Award | A | Stock Option (Right to Buy) | 308,940 | 1.13 | 349.1K | 308,940 | — | ↗ |
| 2024-03-01 | BLATT LAWRENCE | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 965,435 | 1.13 | 1.09M | 965,435 | — | ↗ |
| 2024-02-28 | Symons Julian A. | Officer | A-Award | A | Stock Option (Right to Buy) | 18,750 | 0.96 | 18.0K | 18,750 | — | ↗ |
| 2024-02-28 | Scopa James Paul | Director | A-Award | A | Stock Option (Right to Buy) | 8,823 | 0.96 | 8.5K | 8,823 | — | ↗ |
| 2024-02-28 | Nuechterlein Carole | Director | A-Award | A | Stock Option (Right to Buy) | 4,411 | 0.96 | 4.2K | 4,411 | — | ↗ |
| 2024-02-28 | Nielsen Jack | Director | A-Award | A | Stock Option (Right to Buy) | 4,411 | 0.96 | 4.2K | 4,411 | — | ↗ |
| 2024-02-28 | McClure Matthew W. | Officer | A-Award | A | Stock Option (Right to Buy) | 16,428 | 0.96 | 15.8K | 16,428 | — | ↗ |
| 2024-02-28 | Martell Bridget A | Director | A-Award | A | Stock Option (Right to Buy) | 8,823 | 0.96 | 8.5K | 8,823 | — | ↗ |
| 2024-02-28 | Hirth Peter | Director | A-Award | A | Stock Option (Right to Buy) | 4,411 | 0.96 | 4.2K | 4,411 | — | ↗ |
| 2024-02-28 | Calhoun Lesley Ann | Other | A-Award | A | Stock Option (Right to Buy) | 51,833 | 0.96 | 49.8K | 51,833 | — | ↗ |
| 2024-02-28 | BLATT LAWRENCE | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 132,352 | 0.96 | 127.1K | 132,352 | — | ↗ |
| 2024-02-27 | Symons Julian A. | Officer | D-Return | D | Stock Option (Right to Buy) | 26,250 | 3.06 | 80.3K | 0 | — | ↗ |
| 2024-02-27 | Scopa James Paul | Director | D-Return | D | Stock Option (Right to Buy) | 30,000 | 29.10 | 873.0K | 0 | — | ↗ |
| 2024-02-27 | Nuechterlein Carole | Director | D-Return | D | Stock Option (Right to Buy) | 15,000 | 26.58 | 398.7K | 0 | — | ↗ |
| 2024-02-27 | Nielsen Jack | Director | D-Return | D | Stock Option (Right to Buy) | 15,000 | 26.58 | 398.7K | 0 | — | ↗ |
| 2024-02-27 | McClure Matthew W. | Officer | D-Return | D | Stock Option (Right to Buy) | 23,000 | 3.06 | 70.4K | 0 | — | ↗ |
| 2024-02-27 | Martell Bridget A | Director | D-Return | D | Stock Option (Right to Buy) | 30,000 | 16.52 | 495.6K | 0 | — | ↗ |
| 2024-02-27 | Hirth Peter | Director | D-Return | D | Stock Option (Right to Buy) | 15,000 | 26.58 | 398.7K | 0 | — | ↗ |
| 2024-02-27 | Calhoun Lesley Ann | Other | D-Return | D | Stock Option (Right to Buy) | 26,250 | 3.06 | 80.3K | 0 | — | ↗ |
| 2024-02-27 | BLATT LAWRENCE | Director / Officer | D-Return | D | Stock Option (Right to Buy) | 80,850 | 3.06 | 247.4K | 0 | — | ↗ |
| 2023-10-25 | Scopa James Paul | Director | A-Award | A | Common Stock | 183,083 | 0.76 | 138.6K | 183,083 | — | ↗ |
| 2023-10-25 | ROCHE HOLDING LTD | 10% Owner | — | I | Warrant (Right to Buy) | 3,966,800 | 0.76 | 3.00M | 0 | — | ↗ |
| 2023-10-25 | Nuechterlein Carole | Director / 10% Owner | P-Purchase | A | Warrant (Right to Buy) | 3,966,800 | 0.76 | 3.00M | 3,966,800 | — | ↗ |
| 2023-10-25 | BLATT LAWRENCE | Director / Officer | A-Award | A | Warrants (Right to Buy) | 305,138 | 0.76 | 230.9K | 305,138 | — | ↗ |
| 2023-09-08 | Symons Julian A. | Officer | A-Award | A | Stock Option (Right to Buy) | 48,000 | 0.84 | 40.3K | 48,000 | — | ↗ |
| 2023-09-08 | Quan Lucinda Y. | Officer | A-Award | A | Stock Option (Right to Buy) | 48,000 | 0.84 | 40.3K | 48,000 | — | ↗ |
| 2023-09-08 | McClure Matthew W. | Officer | A-Award | A | Stock Option (Right to Buy) | 48,000 | 0.84 | 40.3K | 48,000 | — | ↗ |
| 2023-09-08 | Calhoun Lesley Ann | — | A-Award | A | Stock Option (Right to Buy) | 48,000 | 0.84 | 40.3K | 48,000 | — | ↗ |
| 2023-09-08 | BLATT LAWRENCE | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 0.84 | 126.0K | 150,000 | — | ↗ |
| 2023-07-20 | Scopa James Paul | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 1.00 | 20.0K | 20,000 | — | ↗ |
| 2023-07-20 | Nuechterlein Carole | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 1.00 | 20.0K | 20,000 | — | ↗ |
| 2023-07-20 | Nielsen Jack | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 1.00 | 20.0K | 20,000 | — | ↗ |
| 2023-07-20 | Martell Bridget A | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 1.00 | 20.0K | 20,000 | — | ↗ |
| 2023-07-20 | Hirth Peter | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 1.00 | 20.0K | 20,000 | — | ↗ |
| 2023-03-15 | Symons Julian A. | Officer | A-Award | A | Stock Option (Right to Buy) | 78,750 | 1.34 | 105.5K | 78,750 | — | ↗ |
| 2023-03-15 | Quan Lucinda Y. | Officer | A-Award | A | Stock Option (Right to Buy) | 78,750 | 1.34 | 105.5K | 78,750 | — | ↗ |
| 2023-03-15 | McClure Matthew W. | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 1.34 | 100.5K | 75,000 | — | ↗ |
| 2023-03-15 | Calhoun Lesley Ann | — | A-Award | A | Stock Option (Right to Buy) | 78,750 | 1.34 | 105.5K | 78,750 | — | ↗ |
| 2023-03-15 | Beigelman Leonid | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 169,500 | 1.34 | 227.1K | 169,500 | — | ↗ |
| 2023-03-15 | BLATT LAWRENCE | Officer | A-Award | A | Stock Option (Right to Buy) | 242,500 | 1.34 | 325.0K | 242,500 | — | ↗ |
| 2022-07-07 | Symons Julian A. | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 1.41 | 70.5K | 50,000 | — | ↗ |
| 2022-07-07 | Quan Lucinda Y. | Officer | A-Award | A | Stock Option (Right to Buy) | 52,500 | 0.00 | — | 52,500 | — | ↗ |
| 2022-07-07 | McClure Matthew W. | Officer | A-Award | A | Stock Option (Right to Buy) | 46,000 | 0.00 | — | 46,000 | — | ↗ |
| 2022-07-07 | Calhoun Lesley Ann | Other | A-Award | A | Stock Option (Right to Buy) | 52,500 | 1.41 | 74.0K | 52,500 | — | ↗ |
| 2022-07-07 | Beigelman Leonid | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 113,000 | 1.41 | 159.3K | 113,000 | — | ↗ |
| 2022-07-07 | BLATT LAWRENCE | Officer | A-Award | A | Stock Option (Right to Buy) | 161,700 | 1.41 | 228.0K | 161,700 | — | ↗ |
| 2022-06-23 | Woiwode Thomas | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-06-23 | Scopa James Paul | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 1.34 | 20.1K | 15,000 | — | ↗ |
| 2022-06-23 | Nuechterlein Carole | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-06-23 | Nielsen Jack | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-06-23 | Martell Bridget A | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 1.34 | 20.1K | 15,000 | — | ↗ |
| 2022-06-23 | Hirth Peter | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-04-27 | McClure Matthew W. | Officer | — | I | Common Stock | 0 | 0.00 | — | 91,204 | — | ↗ |
| 2022-02-04 | Symons Julian A. | Officer | A-Award | A | Stock Option (Right to Buy) | 26,250 | 3.06 | 80.3K | 26,250 | — | ↗ |
| 2022-02-04 | Quan Lucinda Y. | Officer | A-Award | A | Stock Option (Right to Buy) | 26,250 | 3.06 | 80.3K | 26,250 | — | ↗ |
| 2022-02-04 | Calhoun Lesley Ann | — | A-Award | A | Stock Option (Right to Buy) | 26,250 | 3.06 | 80.3K | 26,250 | — | ↗ |
| 2022-02-04 | Beigelman Leonid | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 56,700 | 3.06 | 173.5K | 56,700 | — | ↗ |
| 2022-02-04 | BLATT LAWRENCE | Officer | A-Award | A | Stock Option (Right to Buy) | 80,850 | 3.06 | 247.4K | 80,850 | — | ↗ |
| 2021-11-16 | Martell Bridget A | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 16.52 | 495.6K | 30,000 | — | ↗ |
| 2021-06-17 | Woiwode Thomas | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 26.58 | 398.7K | 15,000 | — | ↗ |
| 2021-06-17 | Nuechterlein Carole | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 26.58 | 398.7K | 15,000 | — | ↗ |
| 2021-06-17 | Nielsen Jack | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 26.58 | 398.7K | 15,000 | — | ↗ |
| 2021-06-17 | Hirth Peter | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 26.58 | 398.7K | 15,000 | — | ↗ |
| 2021-06-11 | Woiwode Thomas | Director | J-Other | D | Common Stock | 485,979 | 0.00 | — | 1,457,937 | — | ↗ |
| 2021-04-26 | Woiwode Thomas | Director | J-Other | A | Common Stock | 9,720 | 0.00 | — | 9,720 | — | ↗ |
| 2021-04-26 | Scopa James Paul | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2020-12-01 | Symons Julian A. | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 16.18 | 3.24M | 200,000 | — | ↗ |
| 2020-12-01 | Quan Lucinda Y. | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 16.18 | 3.24M | 200,000 | — | ↗ |
| 2020-12-01 | Calhoun Lesley Ann | — | A-Award | A | Stock Option (Right to Buy) | 176,237 | 16.18 | 2.85M | 176,237 | — | ↗ |
| 2020-12-01 | Beigelman Leonid | Officer | A-Award | A | Stock Option (Right to Buy) | 300,000 | 0.00 | — | 300,000 | — | ↗ |
| 2020-12-01 | BLATT LAWRENCE | Officer | A-Award | A | Stock Option (Right to Buy) | 450,000 | 16.18 | 7.28M | 450,000 | — | ↗ |
| 2020-10-20 | Woiwode Thomas | Director | C-Conversion | A | Common Stock | 198,839 | 0.00 | — | 2,344,830 | — | ↗ |
| 2020-10-20 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10% Owner | C-Conversion | D | Series B-2 convertible Preferred Stock | 571,143 | 0.00 | — | 0 | — | ↗ |
| 2020-10-20 | Vivo Capital VIII, LLC | 10% Owner | C-Conversion | A | Common Stock | 224,054 | 0.00 | — | 2,633,391 | — | ↗ |
| 2020-10-20 | Versant Venture Capital VI, L.P. | Director | C-Conversion | D | Series B-1 Preferred Stock | 463,959 | 0.00 | — | 0 | — | ↗ |
| 2020-10-20 | Symons Julian A. | Officer | C-Conversion | D | Series B-2 Preferred Stock | 1,452 | 0.00 | — | 0 | — | ↗ |
| 2020-10-20 | Quan Lucinda Y. | Officer | C-Conversion | D | Series B-2 Preferred Stock | 726 | 0.00 | — | 0 | — | ↗ |
| 2020-10-20 | Nuechterlein Carole | Director | C-Conversion | D | Series B-1 Preferred Stock | 662,799 | 0.00 | — | 0 | — | ↗ |
| 2020-10-20 | Novo Holdings A/S | 10% Owner | C-Conversion | D | SERIES B -2 CONVERTIBLE PREFERRED STOCK | 241,219 | 0.00 | — | 0 | — | ↗ |
| 2020-10-20 | Beigelman Leonid | Director / Officer | C-Conversion | D | Series B-1 Preferred Stock | 3,359 | 0.00 | — | 0 | — | ↗ |
| 2020-10-20 | BLATT LAWRENCE | Officer | C-Conversion | A | Common Stock | 21,695 | 0.00 | — | 113,423 | — | ↗ |
| 2020-10-15 | Woiwode Thomas | Director | — | I | Series B-1 Preferred Stock | 463,959 | 0.00 | — | 0 | — | ↗ |
| 2020-10-15 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10% Owner | — | D | Series B-1 convertible Preferred Stock | 1,335,048 | 0.00 | — | 0 | — | ↗ |
| 2020-10-15 | Vivo Capital VIII, LLC | 10% Owner | — | I | Series A Preferred Stock | 260,380 | 0.00 | — | 0 | — | ↗ |
| 2020-10-15 | Versant Venture Capital VI, L.P. | 10% Owner | — | I | Series B-1 Preferred Stock | 463,959 | 0.00 | — | 0 | — | ↗ |
| 2020-10-15 | Symons Julian A. | Officer | — | D | Series A Preferred Stock | 13,671 | 0.00 | — | 0 | — | ↗ |
| 2020-10-15 | Quan Lucinda Y. | Officer | — | I | Series A Preferred Stock | 6,835 | 0.00 | — | 0 | — | ↗ |
| 2020-10-15 | Nuechterlein Carole | Director | — | I | Series B-2 Preferred Stock | 283,550 | 0.00 | — | 0 | — | ↗ |
| 2020-10-15 | Novo Holdings A/S | 10% Owner | — | D | SERIES B-1 CONVERTIBLE PREFERRED STOCK | 563,851 | 0.00 | — | 0 | — | ↗ |
| 2020-10-15 | Nielsen Jack | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-10-15 | Moldt Peter | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-10-15 | Hirth Peter | Director | — | D | Common Stock | 0 | 0.00 | — | 59,549 | — | ↗ |
| 2020-10-15 | Glaub Kathleen Sereda | Director | — | D | Common Stock | 0 | 0.00 | — | 59,550 | — | ↗ |
| 2020-10-15 | Calhoun Lesley Ann | Officer | — | D | Stock Option (Right to Buy) | 52,633 | 3.45 | 181.6K | 0 | — | ↗ |
| 2020-10-15 | Beigelman Leonid | Director / Officer | — | I | Series B-1 Preferred Stock | 3,359 | 0.00 | — | 0 | — | ↗ |
| 2020-10-15 | BLATT LAWRENCE | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 1,237,298 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-12.6K
Shares Outstanding
6.19M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Lawrence M. Blatt, Ph.D., M.B.A. President and Chief Executive Officer | 651.7K | — | — | 3.01M | 371.5K | 19.0K | 4.06M | 74.31% | ↗ |
| 2 | 2025 | Lesley Ann Calhoun Executive Vice President, Chief Operating Officer and Chief Financial Officer | 502.0K | — | — | 874.9K | 190.8K | 12.0K | 1.58M | 55.39% | ↗ |
| 3 | 2025 | Julian Symons, D.Phil. Executive Vice President, Chief Scientific Officer | 492.8K | — | — | 384.5K | 189.2K | 12.0K | 1.08M | 35.65% | ↗ |
| 4 | 2024 | Lawrence M. Blatt, Ph.D., M.B.A. President and Chief Executive Officer | 626.7K | — | — | 1.13M | 361.9K | 17.7K | 2.14M | 52.88% | ↗ |
| 5 | 2024 | Lesley Ann Calhoun Executive Vice President, Chief Operating Officer and Chief Financial Officer | 455.9K | — | — | 361.5K | 190.4K | 12.0K | 1.02M | 35.45% | ↗ |
| 6 | 2024 | Julian Symons, D.Phil. Executive Vice President, Chief Scientific Officer | 487.9K | — | — | 157.1K | 177.6K | 12.0K | 834.5K | 18.82% | ↗ |
| 7 | 2023 | Lawrence M. Blatt, Ph.D. President and Chief Executive Officer | 587.5K | — | — | 311.7K | 393.2K | 52.1K | 1.34M | 23.18% | ↗ |
| 8 | 2023 | Lawrence M. Blatt, Ph.D., M.B.A. President and Chief Executive Officer | 587.5K | — | — | 311.7K | 393.2K | 52.1K | 1.34M | 23.18% | ↗ |
| 9 | 2023 | Leonid Beigelman, Ph.D. Former President | 444.3K | — | — | 156.7K | — | 354.2K | 955.1K | 16.40% | ↗ |
| 10 | 2023 | Matthew McClure, M.D. Executive Vice President, Chief Medical Officer | 482.0K | — | — | 97.3K | 219.8K | 38.6K | 837.7K | 11.62% | ↗ |
| 11 | 2023 | Julian Symons, D.Phil. Executive Vice President, Chief Scientific Officer | 473.7K | — | — | 100.8K | 216.0K | 45.9K | 836.3K | 12.05% | ↗ |
| 12 | 2022 | Lawrence M. Blatt, Ph.D., Chief Executive Officer | 548.7K | — | — | 1.02M | 241.4K | 42.7K | 1.85M | 55.02% | ↗ |
| 13 | 2022 | Lawrence M. Blatt, Ph.D. President and Chief Executive Officer | 548.7K | — | — | 1.02M | 241.4K | 42.7K | 1.85M | 55.02% | ↗ |
| 14 | 2022 | Leonid Beigelman, Ph.D., President | 464.1K | — | — | 713.8K | 167.1K | 33.3K | 1.38M | 51.79% | ↗ |
| 15 | 2022 | Leonid Beigelman, Ph.D. Former President | 464.1K | — | — | 713.8K | 167.1K | 33.3K | 1.38M | 51.79% | ↗ |
| 16 | 2022 | Julian Symons, D.Phil. Executive Vice President, Chief Scientific Officer | 455.5K | — | — | 328.2K | 151.2K | 12.0K | 946.9K | 34.66% | ↗ |
| 17 | 2022 | Julian Symons, D.Phil., Executive Vice President, Chief Scientific Officer | 455.5K | — | — | 328.2K | 151.2K | 12.0K | 946.9K | 34.66% | ↗ |
| 18 | 2021 | Lawrence M. Blatt, Ph.D., Chief Executive Officer | 548.7K | — | — | — | 282.7K | 41.2K | 872.6K | 0.00% | ↗ |
| 19 | 2021 | Leonid Beigelman, Ph.D., President | 464.1K | — | — | — | 195.7K | 42.5K | 702.3K | 0.00% | ↗ |
| 20 | 2021 | Julian Symons, D.Phil., Executive Vice President, Chief Scientific Officer | 435.8K | — | — | — | 165.5K | 17.4K | 618.8K | 0.00% | ↗ |
| 21 | 2021 | Julian Symons, D.Phil. Executive Vice President, Chief Scientific Officer | 435.8K | — | — | — | 165.5K | 17.4K | 618.8K | 0.00% | ↗ |
| 22 | 2020 | Lawrence M. Blatt, Ph.D., Chief Executive Officer | 492.7K | — | — | 6.50M | 364.4K | 43.0K | 7.40M | 87.84% | ↗ |
| 23 | 2020 | Leonid Beigelman, Ph.D., President | 415.0K | — | — | 3.73M | 252.2K | 23.6K | 4.42M | 84.37% | ↗ |
| 24 | 2020 | Julian Symons, D.Phil. Executive Vice President, Chief Scientific Officer | 336.7K | — | — | 2.25M | 210.6K | 32.9K | 2.83M | 79.49% | ↗ |
| 25 | 2019 | Lawrence M. Blatt, Ph.D., Chief Executive Officer | 475.0K | — | — | — | 180.5K | 18.9K | 674.4K | 0.00% | ↗ |
| 26 | 2019 | Leonid Beigelman, Ph.D., President | 400.0K | — | — | — | 152.0K | 3.0K | 555.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Lawrence Blatt | Chief Executive Officer, President & Chairman of the Board | 1M | — |
| Julian A. Symons DPHIL | Executive Vice President & Chief Scientific Officer | 677.5K | — |
| Lesley Ann Calhoun | Executive Vice President, Chief Financial Officer & Chief Operating Officer | 658.2K | female |
| Kristina Engeseth | Senior Vice President and Head of People & Culture | — | female |
| Laura Kavanaugh | Vice President & Head of Legal | — | female |
| Nikhil Aneja | Principal Accounting Officer | — | male |
| Ramon Polo | Senior VP & Head of Global Regulatory Affairs | — | — |
| Sushmita Chanda DABT | Executive Vice President & Chief Development Officer | — | — |
| David Smith | Executive Vice President & Head of Chemical Operations | — | — |
| Tse-I Lin | Senior Vice President of Early Compound Development & Belgian Site Head | — | — |
| James Hassard | Executive VP & Chief Commercial Officer | — | male |
| Kieron Wesson | Vice President & Head of Chemistry Manufacturing Controls | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALGS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
